Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 14/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 15/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16722543 | 0.85 | TLR9 (0.49) | CSNK1DTLR9TLR8TLR7CSNK1E | |
| SCHEMBL18171107 | 0.84 | CSNK1D (0.48) | CSNK1DCSNK1E | |
| SCHEMBL18179666 | 0.81 | CSNK1D (0.39) | CSNK1DTLR9TLR8TLR7CSNK1E | |
| SCHEMBL18179663 | 0.80 | ADORA2A (0.40) | CSNK1DCSNK1ERIPK2LCKKDR | |
| SCHEMBL16728592 | 0.80 | CSNK1D (0.49) | CSNK1DCSNK1E | |
| SCHEMBL18179646 | 0.79 | CSNK1E (0.45) | CSNK1DCSNK1ERIPK2LCKKDR | |
| SCHEMBL18179648 | 0.79 | CSNK1E (0.43) | CSNK1DCSNK1E | |
| SCHEMBL16708913 | 0.77 | RIPK2 (0.51) | CSNK1DCSNK1ERIPK2LCKKDR | |
| SCHEMBL18179653 | 0.75 | CSNK1E (0.42) | CSNK1DCSNK1ERIPK2LCKKDR | |
| SCHEMBL16722733 | 0.75 | CSNK1E (0.61) | CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1D 6/4885TLR9 4828/4885TLR8 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.